Floatz logo

CIS-DIAMMINEDICHLOROPLATINUM II

Blood Cancer

Indapta Therapeutics, INC.Small moleculePhase 3Active
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
89/ 100

Competitive context

8 Active assets in the Blood Cancer cohort.

Asset / SponsorPhaseRating
Benadryl
City of Hope Medical Center
Phase 2BB
Anti-Thymoglobulin, Rabbit
Fred Hutchinson Cancer Center
Phase 2B
Mesna
Indapta Therapeutics, INC.
Phase 2B
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2B
Solu-Cortef
Stanford University
Phase 2B

View all 13 →

Same molecule, other indications

CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:

squamous cell lung carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
adenocarcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →